{"filing":{"accession_number":"0001104659-26-106138","cik":"0001612940","ticker":"PRQR","company_name":"ProQR Therapeutics N.V.","form":"6-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"tm2624953d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1612940/000110465926106138/tm2624953d1_6k.htm"},"events":[{"id":32211,"run_id":29592,"accession_number":"0001104659-26-106138","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"ProQR announced the first participant dosed in the Phase 1 clinical trial of AX-0811, a next-generation RNA editing oligonucleotide for cholestatic liver diseases. This represents a material clinical development milestone—advancement of a lead pipeline program into human testing—that would affect a reasonable investor's assessment of the company's progress and pipeline execution. The announcement also includes expected timing for Phase 1 target engagement data (early January 2027) and details of an investor educational event. This is a discrete operational/clinical milestone rather than a periodic report, earnings release, or other named event type.","company_name":"ProQR Therapeutics N.V.","ticker":"PRQR","filing_date":"2026-09-09","form":"6-K","submitted_at":null,"items":[{"id":35324,"accession_number":"0001104659-26-106138","item_number":"EX-99.1","item_title":"tm2624953d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"ProQR announced the first participant dosed in the Phase 1 clinical trial of AX-0811, a next-generation RNA editing oligonucleotide for cholestatic liver diseases. This represents a material clinical development milestone—advancement of a lead pipeline program into human testing—that would affect a reasonable investor's assessment of the company's progress and pipeline execution. The announcement also includes expected timing for Phase 1 target engagement data (early January 2027) and details of an investor educational event. This is a discrete operational/clinical milestone rather than a periodic report, earnings release, or other named event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T12:05:00.118321+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35324,"accession_number":"0001104659-26-106138","item_number":"EX-99.1","item_title":"tm2624953d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"ProQR announced the first participant dosed in the Phase 1 clinical trial of AX-0811, a next-generation RNA editing oligonucleotide for cholestatic liver diseases. This represents a material clinical development milestone—advancement of a lead pipeline program into human testing—that would affect a reasonable investor's assessment of the company's progress and pipeline execution. The announcement also includes expected timing for Phase 1 target engagement data (early January 2027) and details of an investor educational event. This is a discrete operational/clinical milestone rather than a periodic report, earnings release, or other named event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T12:05:00.118321+00:00","company_name":"ProQR Therapeutics N.V.","ticker":"PRQR","filing_date":"2026-09-09"}]}